ASC42 15 mg ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
93	原発性胆汁性胆管炎	1

93. 原発性胆汁性胆管炎

---

臨床試験数 : 298 /  薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05190523 (ClinicalTrials.gov)	April 6, 2022	13/12/2021	Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis	Primary Biliary Cholangitis	Drug: ASC42 5 mg;Drug: ASC42 10 mg;Drug: ASC42 15 mg;Drug: Placebo	Gannex Pharma Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	100	Phase 2	China